- France
- /
- Healthtech
- /
- ENXTPA:ALMDT
Median Technologies (EPA:ALMDT) shareholder returns have been massive, earning 970% in 3 years
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. One bright shining star stock has been Median Technologies SA (EPA:ALMDT), which is 970% higher than three years ago. In more good news, the share price has risen 13% in thirty days. We love happy stories like this one. The company should be really proud of that performance!
Since the stock has added €24m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.
Check out our latest analysis for Median Technologies
Median Technologies isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last 3 years Median Technologies saw its revenue grow at 36% per year. That's well above most pre-profit companies. And it's not just the revenue that is taking off. The share price is up 120% per year in that time. Despite the strong run, top performers like Median Technologies have been known to go on winning for decades. In fact, it might be time to put it on your watchlist, if you're not already familiar with the stock.
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
If you are thinking of buying or selling Median Technologies stock, you should check out this FREE detailed report on its balance sheet.
A Different Perspective
We're pleased to report that Median Technologies shareholders have received a total shareholder return of 25% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 1.1% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for Median Technologies you should be aware of.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on FR exchanges.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALMDT
Median Technologies
Develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally.
Moderate and overvalued.